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Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) has become a standard treatment of locally advanced rectal
adenocarcinomas.TheclinicalstagesII(cT3-4,N0,M0)andIII(cT1-4,N+,M0)accordingtoInternationalUnionAgainstCancer
(IUCC) are concerned. It can reduce tumor volume and subsequently lead to an increase in complete resections (R0 resections),
shows less toxicity, and improves local control rate. The aim of this review is to summarize actual approaches, main problems, and
discrepancies in the treatment of locally advanced rectal adenocarcinomas.
1. Indicationand Beneﬁt of
NeoadjuvantTreatment
Rectal cancer is one of the most common cancers and
accounts for approximately 1/3 of the deaths due to col-
orectal cancer in 2009 [1]. In well-selected patients (i.e.,
those with well-diﬀerentiated T1 cancers involving <40%
of the circumference, without lymphovascular invasion),
particularly when the only other option is abdominoperineal
resection (APR), local excision seems to be a viable option
[2]. Locally advanced rectal cancer is comprised of tumors
with extension beyond the muscularis propria (≥T3) and/or
those with clinical or pathologic evidence for lymph node
metastasis (N+); in these cases multimodality approaches
are recommended [1]. Such multimodality approaches are
applicable to patients with rectal cancers at or below the
peritoneal reﬂection. This designation generally represents
cancersbelow12cmfromtheanalverge.Generally,thetreat-
ment of tumors localized more than 12cm from anal verge
is based on the colon cancer paradigm. The determination
of “node positivity” in patients with locally advanced rectal
cancer can be diﬃcult. Most lymph nodes involved by rectal
cancerarelessthan1cm,butnotalllymphnodesdetectedby
MRI or TRUS represent metastatic disease; therefore, some
patients can be understaged. Neoadjuvant CRT may also be
considered if the preoperative staging evaluation suggests the
presence of mesorectal invasion [3]. This ﬁnding is highly
predictive of residual tumor at the circumferential margin
[4].
NeoadjuvantCRTismoreeﬀectivethanadjuvanttherapy
in reducing local recurrence and in minimizing toxicity [5].
It is associated with tumor downstaging, signiﬁcantly higher
rate of pathologic complete response (pCR), signiﬁcantly
less advanced pT and pN stage, and fewer cases with
venous, perineural, or lymphatic invasion, increased tumor
resectability [6]. Multivariate analyses conﬁrmed that the
response to neoadjuvant CRT was predictive of improved OS
among the patients with locallyadvanced rectalcancer[7, 8].
Taking advantage of tumor downstaging after neoadjuvant
CRT is supposed to increase the chance of sphincter saving
surgery (SSS) [9]. In fact, this hypothesis is a very complex
issue involving the stage and location of the tumor, the
patient habitus and desire, and the skill of the surgeon. In
a very recent review [9], a total of 17-randomized trials were
analysed, to answer the question if neoadjuvant treatment in
rectal cancer is able to increase SSS. The authors concluded
that the analysis of the most recent and large phase III trials
does not support this hypothesis. The obvious reduction of
permanent stoma in the recent years is according the authors
mainly due to technical and conceptual improvements in the2 Chemotherapy Research and Practice
surgical management of rectal cancers [9]. No data concern-
ing disease progression during treatment were reported in
the large phase III neoadjuvant trials [5, 10, 11].
2. Short- versusLong-Course
NeoadjuvantRadiation
There are two types of neoadjuvant radiation regimens
accepted as standard for resectable rectal cancer: short-
course (5×5Gy)RTalonewithimmediatesurgeryandlong-
course combined CRT with delayed surgery (conventional
radiation doses of 1.8–2Gy per fraction over 5-6 weeks, for a
total dose of 45–50.4Gy) [5].
The Polish trial [12] compared neoadjuvant short-course
RT followed by total mesorectal excision (TME) within 7
days and neoadjuvant long-course CRT followed by TME
at 4–6 weeks. Neoadjuvant short-course RT had less grade
3/4 acute toxicity (3.2 versus 18%), better compliance (97.9
versus69.2%),andsimilarpostoperativetoxicity(28.3versus
27%). Neoadjuvant long-course CRT had higher rate of
pCR (16.1 versus 0.7%) and lower circumferential margin
involvement (4.4 versus 12.9%), which did not translate into
improved survival or recurrence at a median follow up of
48 months. 98% of the patients receiving short-course RT
completed prescribed treatment compared with only 69.2%
of patients receiving CRT [13].
The optimal time interval between RT and surgery is
unknown. There is a trend towards greater downstaging and
complete response with increasing interval between long-
course CRT and surgery [14]. The Lyon 90-01 trial [15]
randomizedpatientswithT2-3mid-andlow-rectalcancerto
neoadjuvant 13×3Gy RT (not short-course RT) followed by
short interval (within 2 weeks) or long interval (6–8 weeks)
to surgery. Long interval arm demonstrated better tumor
response (72 versus 53%) and pathological downstaging
(26 versus 10%). There was a trend towards increased
sphincter preservation in the long-interval group (76 versus
68%) which was not statistically signiﬁcant. There was no
signiﬁcant diﬀerence in 3-year OS (81 versus 73%), local
recurrence (10.3 versus 9.9%), early postoperative mortality
(3 versus 4%), or morbidity (18 versus 17%). In another
multicenter trial, patients were randomized to either short-
course RT (5×5Gy)andsurgerywithin1week,short-course
RTandsurgeryafter4–8weeksorlong-courseRT(25×2Gy)
and surgery after 4–8 weeks. Compliance was acceptable and
severe acute toxicity was low, irrespective of fractionation.
The patients receiving short-course RT with surgery 11–
17 days after the start of RT had the highest complication
rate. These results indicate that surgery should be performed
immediately after short-course RT, within approximately
5 days after the last RT fraction, or be delayed for more
than 4 weeks [16, 17]. A nonsigniﬁcant improvement in
SSS was reported in a French study which randomized
patients to surgery within two weeks after the completion
of RT, compared with six to eight weeks. The long interval
between neoadjuvant RT and surgery provided increased
tumor downstaging with no detrimental eﬀect on toxicity
but did not result in signiﬁcant diﬀerences in long-term local
c o n t r o lo rs u r v i v a l[ 18, 19]. The small number of fractions
makes short-course RT less expensive and more convenient
thanCRT.TheoptimalfractionationofRT,timingofsurgery,
and the best use of concomitant CT remain controversial.
3. Choice of Chemotherapy Regimen
For patients with clinical stage II and III rectal cancer,
neoadjuvant treatment with RT and 5-FU-based CT is
recommended. The integration of newer chemotherapeutic
and targeted agents in patients with advanced colorectal
cancer have led to further improvements in DFS and
OS. These agents are now being studied with RT in the
neoadjuvant therapy of rectal cancer.
Infusional versus bolus 5-FU: infusional rather than
bolus 5-FU during RT increases the likelihood of a pCR in
patients with locally advanced rectal cancer [20].
Orally active ﬂuoropyrimidines versus infusional 5-FU:
recently, results of NSABP R-04 trial have been published.
In the study, 1680 patients were randomly assigned to
the four treatment groups: continuous intravenous infusion
of 5-FU (225mg/m2 5 days per week) with or without
oxaliplatin (5 cycles of 50mg/m2 weekly), or capecitabine
(1650mg/m2 5 days per week) with or without oxaliplatin.
Theauthorsconcludethattheadministrationofcapecitabine
with neoadjuvant RT achieved rates similar to continuous
infusion 5-FU for surgical downstaging, SSS, and pCR.
Furtherresultsofthestudy,includingDFSandOS,shouldbe
available by fall 2013 [21]. In another phase III trial compar-
ing capecitabinewith5-FU foradjuvantorneoadjuvantCRT
for locally advanced rectal cancer [22], results demonstrated
that capecitabine may replace 5-FU in the perioperative
treatment of locally advanced rectal cancer because of the
advantageous safety proﬁle, improved nodal downstaging,
and more favorable survival outcomes seen in the study.
Overall, 392 patients were randomly assigned, 197 to the
capecitabine group and 195 to the 5-FU group. Of these
groups, 81 patients received capecitabine as neoadjuvant
therapy and 80 received 5-FU in addition to TME. Hand-
and-foot syndrome (HFS), fatigue, and proctitis were more
commonly observed in patients in the capecitabine group,
while leucopenia and alopecia were more frequent in the
5-FU group. Rates of diarrhea were similar in patients in
the capecitabine and 5-FU groups during cycles where no
radiation was given, but signiﬁcantly more diarrhea was
noted in patients given capecitabine at the same time as RT
compared with patients administered 5-FU and RT (P =
0.07). After 52 months of follow up, local recurrence rates
were equal in the two arms (6.1% capecitabine and 7.2%
5-FU; P = 0.7795), but fewer patients in the capecitabine
group developed distant metastases (18.8% versus 27.7%;
P = 0.0367). Fifty ﬁve of 93-reported deaths occurred in
patients in the 5-FU arm. Analysis showed that capecitabine
was noninferior compared with 5-FU in 5-year OS, which
was the study’s primary endpoint (75.7% versus 66.6%,
respectively; P = 0.0004). 3-year DFS was superior in the
capecitabine group (75.2%) compared with the 5-FU group
(66.6%; P = 0.034). Development of HFS predicted more
favorable outcomes. In the study, any patient who devel-
oped the skin disorder had signiﬁcantly higher 3-year DFSChemotherapy Research and Practice 3
(83.2%; P = 0.004) and 5-year OS (91.4%; P<0.0001)
compared with patients who did not develop HFS.
Leucovorin: in a retrospective review of 297 patients with
locally advanced rectal cancer treated with 5-FU-based CT
and concurrent RT, the most common CT protocol was
5-FUboluswithleucovorin,bothgivenforﬁvedaysonweeks
1 and 5 of RT. The pCR rate was 15% [23]. In one report of
22 patients with locally advanced rectal cancer treated using
infusional 5-FU combined with leucovorin concurrent with
RT, the pCR rate was 14%. 82% of patients had a SSS, and
3-year survival rate was 69% [24] .T h er o l eo ft h i sd r u gi n
rectal cancer is not so clear.
Oxaliplatin: two-phase III randomized studies have com-
pared the addition of oxaliplatin to either 5-FU (STAR-01)
or capecitabine (ACCORD 12/0405) [25, 26]. The addition
of weekly oxaliplatin signiﬁcantly increased toxicity without
improving the pCR or SSS. Originally designed as a two-
arm study comparing capecitabine with 5-FU, oxaliplatin
was added to the study protocol (known as NSABP R-
04). Although, oxaliplatin has theoretical advantages as a
radiosensitizing agent, no diﬀerence was noted in patients
receiving capecitabine with or without oxaliplatin or 5-FU
with or without oxaliplatin, but greater toxicity was noted
in both oxaliplatin groups [21]. In conclusion, the addition
of oxaliplatin to ﬂuoropyrimidine-based CRT cannot be
considered a standard approach in patients with locally
advanced rectal cancer. Oxaliplatin during RT should not be
used outside clinical trial.
Irinotecan: beneﬁt could not be shown neither for the
addition of irinotecan to 5-FU in patients with locally
advanced rectal cancer in neoadjuvant setting. 106 patients
with locally advanced rectal cancer were randomly assigned
to continuous infusional 5-FU concurrent with hyperfrac-
tionated RT or to infusional 5-FU plus irinotecan and
concurrent conventional fractionation RT [27]. The pCR
rate was similar in both arms. In recently published results
of the phase II trial [28], the rate of pCR of MRI-deﬁned
locally advanced rectal adenocarcinoma using concurrent
irinotecan and capecitabine was 22%. A Radiation Therapy
Oncology Group randomized study compared oxaliplatin
and capecitabine with RT versus irinotecan and capecitabine
with RT. The pCR rates were 18% in the oxaliplatin arm and
10% in the irinotecan arm [29]. Irinotecan has not beneﬁt
in clinical response and moreover increase treatment-related
toxicities.
EGFRinhibitors:overexpressionofEGFRisregardedasa
negativeprognosticfactorandisassociatedwithresistanceto
RT. In retrospective analyses, patients with EGFR-expressing
rectal cancer undergoing neoadjuvant RT had a signiﬁcantly
lower DFS and lower chance of achieving a pCR [30–36].
Two types of EGFR inhibitors have been tested in patients
with locally advanced rectal cancer in neoadjuvant setting:
small-molecule EGFR tyrosine kinase inhibitor (geﬁtinib)
and monoclonal antibody to EGFR (cetuximab).
Geﬁtinib: in a phase I trial from Duke University
combining geﬁtinib, capecitabine, and RT in rectal cancer,
the combination resulted in signiﬁcant toxicity, and no
recommended phase II dose could be determined [37]. In
contrast, an Italian study evaluating infusional 5-FU with
geﬁtinib and RT showed good tolerability with a pCR rate
of 30.3% [38]. Ongoing phase I to II studies are further
evaluating the tolerability and eﬃcacy of geﬁtinib with
conventional neoadjuvant CRT regimens in patients with
locally advanced rectal cancer.
Cetuximab: cetuximab can be safely combined with
RT and CT in the neoadjuvant treatment of rectal cancer.
Two phase II studies investigating cetuximab delivered with
oxaliplatin/capecitabine-based [39] and 5-FU-based [40]
CRT yielded disappointing pCR rates of only 9% and 5%,
respectively. Another study [41] suggests EGF A + 61G poly-
morphism to be a predictive marker for pCR, independent
of KRAS mutation status, to cetuximab-based neoadjuvant
CRT of patients with locally advanced rectal cancer. 130
patients with locally advanced rectal cancer who were
enrolled in phase I/II clinical trials treated with cetuximab-
based CRT were included. Patients with the EGF 61 G/G
genotype had pCR of 45%, compared with 21% in patients
heterozygous, and 2% in patients homozygous for the A/A
allele (P<0.001).
Antiangiogenic agents: increased levels of vascular
endothelial growth factor (VEGF) expression have been
foundinthetumorsandseraofpatientswithlocalizedaswell
as metastatic colon and rectal cancer [42–44]. High VEGF
expression has been associated with disease progression and
inferior survival.
Bevacizumab: the addition of bevacizumab to 5-FU-
based CRT provides encouraging pCR rates and does not
increase acute toxicity [45, 46]. Plasma VEGF (vascular
endothelial growth factor), PlGF (placental-derived growth
factor),sVEGFR1(solublevascularendothelialgrowthfactor
receptor), and IL-6 and CECs (circulating endothelial cells)
should be further evaluated as candidate biomarkers of
response for this regimen [45]. However, the impact of
this strategy on long-term outcomes and posttreatment
complications awaits the completion of phase III studies.
4. Induction Chemotherapy before
Neoadjuvant Chemoradiotherapy in Patients
withLocallyAdvancedRectalCancer
Multimodality treatment for patients with locally advanced
rectal cancer include radiotherapy, chemotherapy, chemora-
diotherapy, surgery, and eventual incorporation of molec-
ularly targeted agents. The optimum sequence of these
modalities is being discussed. Moreover, rectal cancer local
recurrence rates are today less than 10%. The predominant
mode of failure in rectal cancer is the development of distant
metastases (30–35%). Therefore, the primary goal of adding
induction CT is not to improve local eﬃcacy, but to better
control distant disease [5, 47]. The neoadjuvant RT/CRT has
been shown to be superior to adjuvant treatment for variety
of endpoints [5, 48]. Another consideration to underline is
thesuboptimalcomplianceofsystemictreatmentinadjuvant
setting. Approximately 50% of patients are unable to receive
the planned adjuvant CT dose [5, 10, 11, 49, 50]. Two
common reasons for this are toxicity and patient refusal.
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reached during neoadjuvant RT are substantially lower than
in adjuvant colon cancer trials, an innovative approach
such as to deliver systemic therapy prior to neoadjuvant
CRT was developed [5, 10, 11, 49, 50]. Induction CT
may be associated with better treatment compliance and
may enable full systemic doses of CT to be delivered.
Other theoretical advantages of induction CT include the
possibility of tumor shrinking or downstaging, thereby
facilitatingmoreeﬀectivelocaltreatmentandearlytreatment
of micrometastasis. Tumor shrinkage potentially allows
improved tumor vascularity. Theoretically, the consequences
of this are improved oxygenation and higher intratumoral
concentration of cytotoxic drugs [51, 52]. Another theoret-
ical advantage of induction CT is the potential to eradicate
distant micrometastases at an early stage in the evolution,
utilization of the embryonic tumor blood supply (in contrast
to surgical scars), and treatment of ﬁt patient before surgery
[53]. On the other hand, this strategy may be associated
with the selection of radioresistant clones, the induction
of accelerated repopulation, possibly reduced compliance to
CRT, and a substantial delay of deﬁnitive surgery [53].
Recently, a Spanish randomized phase II trial compared
the induction CT approach with conventional neoadjuvant
CRT followed by surgery and adjuvant CT. A total of 108
patients with locally advanced resectable rectal adenocar-
cinoma were randomly assigned to: arm A: preoperative
CRT (5 weeks, capecitabine 1650mg/m2 5 days/week +
oxaliplatin 50mg/m2 weekly, pelvic RT: 50.4Gy), followed
by surgery after 5-6 weeks and adjuvant CRT CAPOX (4
cycles, capecitabine 2000mg/m2 for 14 days, oxaliplatin
130mg/m2 day 1). Arm B: induction CAPOX (4 cycles,
capecitabine 2000mg/m2 for 14 days, oxaliplatin 130mg/m2
day 1) followed by CRT (5 weeks, capecitabine 1650mg/m2
5 days/week + oxaliplatin 50mg/m2 weekly, pelvic RT:
50.4Gy), followed by surgery after 5-6 weeks. The primary
endpointwaspCR.ComparedwithadjuvantCAPOX,induc-
tion CAPOX before CRT had similar pCR and complete
resectionrates. It did achieve more favorablecompliance and
toxicity proﬁles [54]. Chau et al. published clinical results
of phase II trials (ﬁrst published in 2006 with 77 patients
updated in 2010 with 105 patients). He examined the use
of 4 cycles of induction CT CAPOX (oxaliplatin 130mg/m2
day 1 with capecitabine 2000mg/m2 daily for 14 days
every 3 weeks) followed by CRT (54Gy over 6 weeks with
capecitabine1650mg/m2 daily),followedbytotalmesorectal
excision,and12weeksofadjuvantcapecitabine(2500mg/m2
daily for 14 days every 3 weeks). The primary endpoint was
pCR. Radiological response rates after induction CT and
CRT were 74% and 89%, respectively. 3-year progression-
free and overall survival were 68% and 83%, respectively.
A 20 % pCR was reported. A major concern of this study
is that nine patients had cardiac and thromboembolic toxic
eﬀects, leading to four deaths during induction CT; however,
other trials with induction CT did not conﬁrm such a
high number of early fatal events [55]. Another phase
II study evaluated the eﬃcacy and safety of neoadjuvant
capecitabine plus oxaliplatin and RT in patients with locally
advanced rectal cancer. Treatment consisted of one cycle of
XELOX(capecitabine1000mgm2 for14daysandoxaliplatin
130mgm2 day 1), followed by RT (1.8Gy fractions 5 days
p e rw e e kf o r5w e e k s )p l u sC A P O X( c a p e c i t a b i n e8 2 5m gm 2
on days 22–35 and 43–56, and oxaliplatin 50mgm2 on days
22, 29, 43, and 50). Surgery was recommended 5 weeks after
the completion of CRT. The primary endpoint was pCR.
Sixty patients were enrolled. The pCR rate was 23%, and
R0 resection was achieved in 98% of patients. Sphincter
preservation was achieved in 84% of patients. Tumor and/or
nodal downstaging was observed in 65% of patients. The
most common grade 3/4 adverse events were diarrhea
(20%) and lymphocytopaenia (43%) [56]. Another Spanish
study compared eﬃcacy in terms of pathologic response
in patients with locally advanced rectal cancer treated with
neoadjuvant CRT, with or without a short-intense course
of induction oxaliplatin. 114 patients were treated with
neoadjuvant CRT (45–50.4Gy + oral Tegafur 1200mg/day).
52 patients additionally received induction FOLFOX-4 (2
cycles), followed by the previously described Tegafur CRT
regime. Surgery was performed in 5-6 weeks. Incidence of
pT(0) specimens was signiﬁcantly increased by induction
FOLFOX-4(P = 0.006).TotalTandNdownstagingwas58%
versus 75% and 42% versus 40%, respectively (P = ns). T
downstaging of > or = 2 categories was signiﬁcantly superior
in FOLFOX-4 group (P = 0.029). The authors conclude that
short-intense induction FOLFOX-4 signiﬁcantly improves
pCR in patients with locally advanced rectal cancer treated
with tegafur-sensitized neoadjuvant CRT [57].
In conclusion, the induction CT in patients with locally
advanced rectal cancer is feasible, does not compromise CRT
or surgical resection, and enables CT to be delivered in
adequate dose and intensity. A phase III study to deﬁnitively
test the induction strategy is warranted.
5.ThePrognosticImpactofTumorRegression
M o d e r nn e o a d j u v a n tc o n c u r r e n tC R Tt r e a t m e n tr e g i m e n s
have consistently demonstrated pCR rates of up to 20%
[58, 59]. The Gastro-Intestinal Working Group of the
Italian Association of Radiation Oncology collected clinical
data for 566 patients with pCR after neoadjuvant therapy.
Locoregional recurrence occurred in 7 patients (1.6%) and
distant metastases in 49 patients (8.9%). Overall, 5-year rates
of DFS and OS were 85% and 90%, respectively. These data
conﬁrm that in a large series of patients achieving pCR after
neoadjuvant therapy, highly favorable outcomes are achieved
[60]. Investigators from Memorial Sloan Kettering Cancer
Center reported that response to neoadjuvant therapy was
as t r o n gp r e d i c t o ro fD F S .H o w e v e r ,o u t c o m ew a sm o s t
accurately estimated by ﬁnal pathologic stage, which is
inﬂuenced by both preoperative stage and response to
therapy [61]. These results indicate that pathologic stage
is still the most reliable predictor of survival in patients
undergoing neoadjuvant CRT and surgery. The pCR appears
to be associated with a very favorable prognosis. The degree
of regression has been correlated to long-term survival
outcomes. In a subgroup of patients from the German Rectal
Cancer Trial, 5-year DFS ranged from 86% for patients with
complete tumor regression, to 75% for patients with 25–
75% tumor regression, and 63% for patients with <25%Chemotherapy Research and Practice 5
tumor regression (P = 0.006) [62]. Furthermore, OS was
improved with downstaging (P = 0.003), and the persis-
tence of positive lymph node involvement after treatment
was strongly associated with a higher risk of recurrence
(P<0.001) [63]. Recognizing the prognostic importance
of tumor regression, the Tumor Regression Grade (TRG)
classiﬁcation became an essential component of the protocol
forpathologicreportingofrectalcancerresectionspecimens.
There is a question whether selected patients with
radiologic and clinical evidence of a complete response
after neoadjuvant CRT might be able to avoid surgery. No
randomized trials are available. As it is sure that some
patients with clinical complete response have microscopic
residual tumor at resection, at the present, surgery remains
the standard approach after neoadjuvant CRT, even in
patients who appear to have a complete clinical response to
neoadjuvant therapy.
6. AdjuvantChemotherapy after
Neoadjuvant Therapy for Rectal Cancer?
There is insuﬃcient evidence on the beneﬁt of adjuvant
CT after neoadjuvant CRT for rectal cancer. The main
advantage of adjuvant CT is better selection of patients since
it can be based on pathologic staging [64]. In addition, the
high rate of failure in terms of distant metastases suggests
that residual malignant cells either in the primary site or
elsewher ema yr equir emor eeﬀectiveandadditionalsystemic
methods of elimination [53]. The primary disadvantages
include increased toxicity [64] which may compromise the
dose intensity of adjuvant CT [53], and the compliance of
adjuvant CT is suboptimal [10, 11].
The beneﬁt of 5-FU-based adjuvant CT in patients with
locally advanced rectal cancer undergoing neoadjuvant CRT
remainsuncertain,althoughmostoncologistsrecommendit.
NCCN guidelines recommend that all such patients should
receive adjuvant CT even if they have a pCR after neoadju-
vant therapy [65]. The choice of regimen is unsettled. ESMO
guidelinesstatedthat“similartothesituationincoloncancer
stages III (and “high-risk” stage II), adjuvant CT can be
provided, even if the scientiﬁc support for suﬃcient eﬀect is
less.” It appears as if the eﬃcacy of adjuvant CT is less if the
tumorshavenotrespondedtotheneoadjuvantRT/CRT[66].
Experts of European Rectal Cancer Conference (EURECA-
CC2) acknowledged that there is an insuﬃcient evidence
on the beneﬁt of adjuvant CT after neoadjuvant CRT to
come to consensus about its use [67]. Subgroup analysis
suggests that only patients who respond and are downstaged
from cT3-4 to ypT0-2 beneﬁt from 5-FU-based adjuvant CT
[68]. Survival beneﬁt of 3-4% with 5-FU-based adjuvant CT
was reported [69]. EORTC 22921 randomised trial failed to
conﬁrm a beneﬁt of adjuvant CT in patients with locally
advanced rectal cancer after neoadjuvant CRT in the terms
of DFS or OS [11], even in the node-positive patients [68].
Data of 785 of the 1,011 randomly assigned patients whose
diseasewasM0atcurativesurgerywereused. Althoughthere
was no statistically signiﬁcant impact of adjuvant CT on
DFS for the whole group (P>0.5), the treatment eﬀect
diﬀered signiﬁcantly between the ypT0-2 and the ypT3-4
patients, only the ypT0-2 patients seemed to beneﬁt from
adjuvant CT (P = 0.011). The same pattern was observed for
OS. Exploratory analyses suggest that only good-prognosis
patients (ypT0-2) beneﬁt from adjuvant CT. Patients in
whom no downstaging was achieved did not beneﬁt. This
also suggests that the same prognostic factors may drive both
tumor sensitivity for the primary treatment and long-term
clinical beneﬁt from further adjuvant CT [68]. Also Janjan
et al. [8] suggested that patients who responded to 5-FU
during neoadjuvant CRT probably would also respond to
5-FU-based adjuvant CT. It has been frequently observed
that a large number of patients who remain in a node-
positive stage after neoadjuvant CRT and surgery for rectal
cancer developed early distant metastases and not local
recurrence despite of continuing adjuvant CT [70]. Patients
downstaged to ypT0-2N0 disease after CRT or after RT alone
have a favourable prognosis [60, 71–73]. For these reasons,
according to some authors, the gain in absolute percentages
from adjuvant CT in those groups is very small [74]. It
was reported that adding adjuvant CT did not signiﬁcantly
improve DFS or OS for patients with a good response (ypT0-
2N0) following neoadjuvant CRT and curative surgery [75].
These ﬁndings are consistent with suggestion by Das et
al. [76]t h a ta d j u v a n tC Tm a yb eo fg r e a t e rb e n e ﬁ tf o r
high-risk patients. Bujko et al. underlined some interesting
consideration about EORTC 22921 trial [74]. The ﬁrst point
was that the intention-to-treat principle was not followed as
22% patients were excluded from the analysis. Furthermore,
the numbers of patients in whom the beneﬁt of CT was
found (ypT0-2 disease) were imbalanced in the adjuvant CT
groupversusthecontrolgroup(198versus225,respectively).
Also, the beneﬁcial eﬀect of adjuvant CT was conﬁned
onlytoypT0-2patientsreceivingconventionallyfractionated
neoadjuvant RT and not those receiving neoadjuvant CRT
[77]. A pooled retrospective analysis reported 566 patients
with advanced rectal cancer with pCR after neoadjuvant
RT or CRT [60]. Unexpectedly, a tendency towards worse
DFS was noted in the 22% of patients given adjuvant CT,
comparedwith thosenot receiving this treatment. Therefore,
the concept of the EORTC trial subgroup analysis that
adjuvant CT provides a beneﬁt in patients downstaged after
RT/CRT is dubious [74]. The aim of the QUASAR trial
[69] was to determine survival beneﬁt from adjuvant CT
for patients with colorectal cancer at low risk of recurrence,
for whom the indication for such treatment is unclear. After
apparently curative resections of colon or rectal cancer, 3239
patients (2963 with stage II disease, 2291 with colon cancer),
were randomly assigned to receive CT with 5-FU and folinic
acid (n = 1622) or to observation (n = 1617). The primary
outcome was all-cause mortality. After a median follow up
of 5.5 years, there were 311 deaths in the CT group and 370
in the observation group; the relative risk of death from any
cause with CT versus observation alone was 0.82 (95% CI
0.70–0.95; P = 0.008). There were 293 recurrences in the
CT group and 359 in the observation group; the relative
risk of recurrence with CT versus observation alone was
0.78 (0.67–0.91; P = 0.001). The authors concluded that
CT with 5-FU and folinic acid could improve the survival
of patients with stage II colorectal cancer although the6 Chemotherapy Research and Practice
absolute improvements are small (an absolute improvement
in survival of 3.6%) [74].
Another clinically relevant question is whether the
indication for adjuvant CT should be determined by clinical
staging (cTNM) or by the deﬁnitive pathological surgical
staging (ypTNM). Several reports have shown that the
postoperative pathological staging after CRT is more dis-
criminative for prognosis than the pretreatment clinical
staging [60, 61, 72].
The role of adjuvant CT following neoadjuvant CRT
and radical surgery for patients with locally advanced rectal
cancer remains unclear. Randomized trials are needed.
7. The Problem of Low-Risk
T3N0M0 Rectal Tumors
A number of studies [78–80] have demonstrated that
patients undergoing resection of pT3N0 rectal cancer with
favorable pathologic features experience a low rate of local
failure after surgery alone, suggesting that these patients
may not require adjuvant therapy. A ten-year actuarial local
recurrence rate of these patients is less than 10% [81]. Gun-
derson et al. reported a retrospective analysis of pooled data
demonstrating similar 5-year OS for pT3N0 rectal cancer
patients treated with surgery and CT alone (84%) versus
those treated with CRT (74% to 80%), further suggesting
that trimodality therapy may be excessive for some patients
in the T3N0 subset [82]. In the study of Lombardi et al.,
the authors found that 28% of patients with rectal cancer
clinically staged as cT3N0 before CRT were identiﬁed to have
lymph node metastases at surgical pathology. In the large
multicenterstudy,22%ofpatientsstagedbeforeneoadjuvant
CRT as having cT3N0 rectal cancer on either EUS or MRI
have pathologically positive lymph nodes [83]. This subset
of patients diﬀers from the remaining true node-negative
patients [84]. In meta-analysis of 90 imaging studies that
aimed to compare EUS, CT, and MRI performance for rectal
cancer staging were found low sensitivity values for nodal
staging without statistically signiﬁcant diﬀerences between
each modality. Sensitivity estimates for EUS, CT, and MRI
were 67, 55, and 66%, respectively. Speciﬁcity values were
also comparable: 78% for EUS, 74% for CT, and 76% for
MRI [85]. The German study [5] demonstrated that 18%
of patients staged clinically as having cT3, cT4, or node-
positive rectal cancer on EUS were overstaged. Because
neoadjuvant CRT may not only reduce the total number of
LNsbutalsosterilizemesorectalLNs[86–88],thetruerateof
unidentiﬁedpathologicallyinvolvedLNsislikelytobehigher
[83]. Adverse prognostic features, including a greater depth
of perirectal fat invasion, poor tumor diﬀerentiation, the
presence of lymphovascular invasion, abnormally elevated
pretreatment carcinoembryonic antigen levels (>5ng/mL),
circumferential margin involvement, and a low-lying posi-
tion may identify T3N0 patients at high risk for local
recurrence who may beneﬁt from the addition of radiation
therapy. The pretherapy detection of unfavourable features
would lead to the delivery of adjuvant CRT. It is unlikely
thatapretherapybiopsywouldreliablyexcludeunfavourable
pathologic features [83]. An alternative method for iden-
tifying positive nodes would be the analysis of molecular
markers which is very limited nowadays [83]—for example,
tumor location, P21, CD44v6 [89]. On the other hand,
neoadjuvant CRT could be a likely overtreatment in the
subgroup of T3N0 tumors with favourable features (low risk
ofCRMinvolvementandlocationinthemid/upperrectum).
Accuratepretreatmentidentiﬁcationofnode-negativecancer
and subdivision of cT3N0 tumors into diﬀerent substages
are fundamental requirements in evaluating the eﬃcacy and
safety of tailored treatments [84].
Some institutions consider neoadjuvant short-course RT
a valid alternative in patients with cT3 rectal cancer whose
disease does not need downsizing (not threatened by CRM,
located in the upper and mild rectum), also because of the
possibility of choosing the proper adjuvant CT on the basis
of pathological data [90].
Accurate pretreatment identiﬁcation of node-negative
cancer and subdivision of cT3N0 tumors into diﬀerent
substages are fundamental requirements in evaluating the
eﬃcacy and safety of tailored treatments [84]. Thus, neoad-
juvant CRT shoud remain the care standard for locally
advanced rectal cancer, including cT3N0 on the grounds
of the principle that overtreatment is less hazardous than
undertreatment for cT3N0 rectal cancers (5) [84]. The
optimal treatment for these truly superﬁcial uT3 lesions
warrants further study in the form of a randomized trial.
8. Qualityof Lifeand TreatmentToxicity
The adverse eﬀects after treatment for rectal cancer
include gastrointestinal disorders, genitourinary and sexual
dysfunction, and secondary cancers, pelvic or hip fractures,
and thromboembolic diseases [91–95].
8.1.GastrointestinalDisorders. Thesymptomsresultingfrom
adverse eﬀects of the gastrointestinal tract include diarrhea,
bleeding, abdominal pain and obstruction due to stenosis
or adhesions and more rarely malabsorption [96], necrosis,
perforation, and ﬁstulation [97]. The incidence of small
bowel obstruction requiring surgery following adjuvant
pelvic RT for rectal cancer is 4–15% in historical series [67].
Anal and rectal dysfunction refers mainly to symptoms such
as gas, liquids or solid faeces incontinence, rectal emptying
problems, frequent bowel movements, and diarrhea. The
long-term bowel function is impaired more by adjuvant
RT than by neoadjuvant RT [5]. Patients with stomas were
more satisﬁed with their bowel function than those operated
with a low anterior resection without stoma; those were
independent of RT [20, 92]. In a Polish trial comparing
neoadjuvant short-course RT and CRT, no diﬀerences were
seen in the proportion of patients having incontinence to
loose stools (72% RT and 65% CRT), diﬃculties in discrim-
ination between gas and stools (59% RT and 66% CRT) and
in stool frequency (median 4 RT and 5 CRT). This study
did not reveal any diﬀerences in late adverse eﬀects from the
gastrointestinal tract [13]. Other gastrointestinal disorders
include ﬁstulas and anastomotic strictures. Adjuvant CRTChemotherapy Research and Practice 7
increased the risk of late anastomotic strictures (12%)
compared to neoadjuvant CRT (4%, P = 0.003) [5].
8.2. Genitourinary Dysfunction. Urogenital dysfunction after
rectal cancer treatment is common. It include, incontinence,
retention, dysuria, frequency and urgency [98, 99]. Late
urinarytractsymptomswerereportedin4%ofallpatientsin
theWesternNorwegiantrial[100]andin3%ofallpatientsin
the Uppsala trial, with chronic cystitis as the most common
diagnosis [101]. Bladder problems were seen in 2% of the
preoperatively treated and 4% of the postoperatively treated
patients (P = 0.21) in the German study on pre- versus
postoperative CRT [5].
8.3. Sexual Dysfunction. As with surgery, RT can lead to
increased sexual dysfunction. In males, a long-term deteri-
oration of ejaculatory and erectile function is due to late
radiation damage to the seminal vesicles and small vessels,
respectively. In females, RT leads to vaginal dryness and
diminished sexual satisfaction [102]. Patients who undergo
an APR have more voiding diﬃculties, erectile dysfunction,
and dyspareunia, compared with those who undergo a
LAR [102]. Dutch TME trial analysed the grade of sexual
dysfunction between irradiated and surgery only patients
[102]. In males, the sexual activities of those who were
still active preoperatively decreased to 67% in irradiated
patients and 76% in nonirradiated patients: this diﬀerence
was not statistically signiﬁcant. A greater diﬀerence was seen
in females with a reduction to 72% for irradiated patients
and 90% nonirradiated patients.
8.4. Second Cancers. The risk was mainly related to second
cancers from organs within or adjacent to the irradiated
target. There was no individual type of cancer that could
be related to the RT, but gynaecologic and prostate cancers
were the most common second cancers from organs within
or adjacent to the irradiated target [94].
Gender diﬀerences in quality of life of patients after
treatment for rectal cancer have been previously reported.
Women have higher rates for fatigue and insomnia as shown
in general population. Men appear to have higher scores
of sexual problems, but somewhat higher scores for sexual
functioning than female [102]. The multicenter prospective
observational trial [103] evaluating quality of life in patients
with rectal cancer who receive neoadjuvant CRT. Only 14%
of patients had optimal continence. Physical/social function-
ing, fatigue, and body image showed a decrease just after
neoadjuvant CRT and returned to baseline levels at 1 year
after treatment. Global quality of life was stable over time.
Male sexual problems were greatly impaired throughout the
study period (P<0.001) with major clinically meaningful
changes between baseline and 1 year after treatment.
In conclusion, neoadjuvant/adjuvant treatment for
locally advanced rectal cancer can have some negative eﬀects
on quality of life that should be discussed with the patient
before the deﬁnitive choice of treatment.
9.RiskFactorsAssociatedwith
LocalRecurrence
Due to diﬀerences in the lymphatic drainage and the
narrow anatomic space of the true pelvis, rectal cancer
behaves diﬀerently from colon cancer, particularly with
regard to an increased risk for local recurrence [104, 105].
Important prognostic factors following complete tumor
excision include the lack of distant metastases (M stage),
the depth of inﬁltration into the rectal wall (T stage), the
number and localization of involved lymph nodes (N stage),
the circumferential radial margin (CRM), and a positive
distal margin [106]. Pathologic ﬁndings like lymphovascular
invasion and poor diﬀerentiation have also been shown to
increase the risk of local recurrence [107, 108]. A positive
microscopic margin is deﬁned as histological evidence of
tumor in the line of resection and results in local recurrence
rates ranging from 31 to 55% [109–111]. Some authors have
advocated that a CRM of 1 or 2mm should be viewed as a
positive margin because high local recurrence are reported
with a 0.1 to 1mm margin (7–28%) and with a 1.1 to
2mm margin (5–15%) [109–111]. For distal rectal cancer, a
clear distal margin of 1cm is thought to be an oncologically
adequate resection in patients who received neoadjuvant
CRT [112]. Finally, patients who undergo APR tend to have
a higher positive CRM rate than those who undergo SSS
[113]. Local excision was also associated with increased local
recurrence rates, particularly when excision was performed
for more advanced-stage tumors (such as any tumor greater
thanaT1)orcancerswithpoorprognosticpathologicfactors
(such as neurovascular invasion). Leibold et al. examined
the prognostic signiﬁcance of the location of involved
lymph nodes in 121 rectal cancer patients (uT3-4 and/or
N+) following neoadjuvant CRT [114]. The data suggested
that, following neoadjuvant CRT, proximal lymph node
involvement (those lymph nodes along the major supplying
vessels, in contradistinction to the mesorectal lymph nodes)
is associated with a high incidence of metastatic disease at
time of surgery.
Other prognostic parameters (e.g., newer molecular
markers, genetic signatures, etc.) are of interest but cannot
yet be regarded as a routine part of clinical decision making.
10. Issues for the Future
Unfortunately, neoadjuvant CRT is not beneﬁcial for all
patients. The treatment response ranges from a pCR to a
resistance. It is reported that 10 to 20 percent of patients
with advanced rectal cancer show pCR to neoadjuvant
CRT [58, 59]. In addition, complete or near-complete
response to neoadjuvant CRT is indicative of improved
long-term prognosis [59, 115]. Nowadays, it is not possible
to identify patients with no or minimum tumor response
to neoadjuvant CRT before its initiation. Based on our
data, group of nonresponders represents approximately 12%
of all patients [116]. Although several molecular markers
have been investigated as potential predictors of therapeutic
responses, no marker has been consistently identiﬁed as
clinically applicable. In the future, molecular predictors and8 Chemotherapy Research and Practice
improved imaging could be used to individualize the therapy
of patients with locally advanced rectal adenocarcinomas,
and thus in a selected group of nonresponders avoid the
delay of surgical intervention and the eventual toxicity of
the neoadjuvant therapy. Integration of targeted therapies,
newer cytotoxic agents, and a more selective approach to the
use of adjuvant chemo-targeted therapy strategies should be
deﬁned.
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